A pivotal study of Evenamide (NW-3509) in schizophrenia

Trial Profile

A pivotal study of Evenamide (NW-3509) in schizophrenia

Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Newron Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2017 New trial record
    • 26 Sep 2017 According to a Newron Pharmaceuticals media release, the company is completing the design of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top